Wednesday, May 4, 2011

Onyx returns rights to 2 cancer drugs to Singapore partner

Onyx Pharmaceuticals Inc. has pulled out of a two-year-old deal — once pegged to be worth $550 million — with a Singapore partner on a set of possible cancer drugs.
South San Francisco-based Onyx (NASDAQ: ONXX) remains a shareholder in S-Bio Pte Ltd. but will return the North American and European rights to the S*Bio drugs SB-1518 and SB-1578.

No comments:

Post a Comment